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Abstract
Background Allergen immunotherapy has proven to
be efficacious in allergic rhinitis and asthma. How-
ever, results from randomised clinical trials may vary
substantially. Clinical trials may unexpectedly fail.
The purpose of this review is to discuss the possible
factors that may contribute to a successful or unsuc-
cessful study.
Methods Descriptive review exploring the possible
causes of negative outcomes in allergen immunother-
apy trials.
Results A series of factors may lead to negative results.
Among of these are underpowering of the study, low
allergen content in tested extracts, insufficient aller-
gen exposure during monitoring and recruitment of
inappropriate patients. In addition, the choice of the
primary endpoint may be critical.
Discussion A clinical trial aims to evaluate the efficacy
of an agent. However, studies with potential effective
compounds may fail because of methodical issues.
Sometimes, they are the cause of discrepancies be-
tween successful phase II and unsuccessful phase III
trials. To understand more about failure of studies, in-
vestigators and editors should be encouraged to pub-
lish negative trials.
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CONSORT Consolidated Standards of Reporting
Trials
GAP Grass SLIT tablet Asthma Prevention
HDM House dust mite
ITT Intention-to-treat
OR Odds ratio
PAT Preventive Allergy Treatment
RCT Randomised clinical trial
RCT Randomised controlled trial
SCIT Subcutaneous immunotherapy
SLIT Sublingual immunotherapy
TCS Total combined symptom score
Introduction
Allergen immunotherapy (AIT) already exists for more
than a century. Leonard Noon described the first in-
oculation with grass pollen extract demonstrating that
repeated subcutaneous injection leads to diminished
conjunctival sensitivity [1]. The first randomised
controlled trial (RCT) of subcutaneous grass pollen
immunotherapy was performed by William Frankland
[2]. He successfully demonstrated the superiority
of grass pollen extract over placebo. In later years
much attention has been paid to alternative routes
of administration. In 1986 the first double blind,
placebo-controlled sublingual AIT in patients with
allergic rhinitis due to house dust mite demonstrated
diminished nasal responsiveness to house dust mites
following active treatment [3].
Although subcutaneous and sublingual allergen
immunotherapy for both rhinitis [4] and asthma [5]
have proven efficacy as demonstrated in recent large
systematic reviews, a wide variation in study results
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can be seen. Meta-analyses from AIT studies are also
characterised by considerable heterogeneity [6, 7].
AIT may simply not work because the newly tested
compound is not capable to induce a therapeutic ef-
fect. An effect can be unexpected. For instance, in-
tradermal grass pollen extract immunotherapy led to
the suppression of late phase skin reactions, whereas
there was no difference in primary endpoint (symp-
tom-medication score) between active and placebo
treatment [8]. Paradoxically, some secondary end-
points were worse in the intradermal immunotherapy
group (nasal symptoms, visual analogue scale, asthma
symptoms and symptom free days).
Although the outcome of a randomised clinical trial
will be determined by the efficacy of the active com-
pound, other factors may influence the result of an
AIT trial. The purpose of this paper is to discuss the
possible factors that may contribute to a successful or
unsuccessful study (Table 1).
Possible factors that may influence the outcome
an AIT trial
Underpowering
A study should be well designed and well powered.
Bousquet et al. analysed 46 subcutaneous (SCIT) and
48 sublingual (SLIT) double blind, placebo-controlled
randomised immunotherapy trials [9] using the Con-
solidated Standards of Reporting Trials (CONSORT)
checklist. These trials were published between 1996
and 2009. Important flaws in the reports were the
absence of a flowchart and description of dropouts,
inadequate or incomplete randomisation, absence
of a power-analysis, absence of an intention-to-treat
(ITT) analysis or the use of a modified ITT analysis.
Most striking was that in 33 and 27% respectively of
the SCIT and SLIT studies a power analysis was not
reported.
Underpowering has been put forward as one of
the explanations for a negative sublingual AIT study
among asthmatic children [10]. Particularly, when two
active treatments are compared a power calculation
is crucial. In a placebo-controlled, double-dummy
study both birch pollen SCIT and SLIT appeared su-
perior to placebo; however a significant difference be-
tween both treatments could not be found [11]. The
authors indeed state that to demonstrate a difference
larger groups than the 19 SCIT and 15 SLIT patients
should be included.
Allergen content of the tested agent
An important reason for ineffective treatment may be
the lack of sufficient allergen content. When com-
paring extracts from different manufacturers a wide
variation in allergen content can be found. In a study
on allergen content of grass pollen preparations for
sublingual immunotherapy the differences between
Table 1 Reasons for an unsuccessful allergen im-
munotherapy (AIT) study
The study is underpowered
The tested agent does not contain sufficient allergen or the agent has been
administered too infrequently
Participants are not sufficiently exposed to the culprit allergen during the
assessment phase
There are flaws in the recruitment of participants, for instance too many
patients with mild disease are included
The primary endpoint is not met (from a regulator’s point of view) and/or
the primary endpoint is not appropriate for the study
the immunotherapeutics with the lowest vs highest
maintenance dose amounted to a factor of 31 for pro-
tein, 26–60 for allergen, depending on the used serum
pool, and up to 108 for the daily Phl p 5 dosages [12].
Such differences may easily explain the heterogeneity
in study results often seen in AIT trials.
Also extracts containing sufficient amounts of aller-
gen may be unsuccessful if the frequency of adminis-
tration is too low to demonstrate a substantial clinical
effect. Examples are a 2-year grass pollen tablet study
with only clinical efficacy in the 2nd year using the
grass pollen tablets 3 times per week [13] and a neg-
ative grass pollen drops study among children and
adolescents, administering 2 doses per week [14].
Allergen exposure
It is clear that without sufficient natural allergen ex-
posure a study on the efficacy of AIT is doomed to fail.
A well-designed phase II/III randomised clinical trial
(RCT) evaluating 2 maintenance doses of immuno-
logically enhanced standardised quality grass pollen
immunotherapy failed to demonstrate efficacy com-
pared with placebo in spite of dose-dependent in-
creases in IgG4 and blocking antibodies, which were
comparable with previous grass SCIT and grass SLIT
tablet trials [15]. The inconclusive results were most
probably influenced by a very low grass pollen season
with a mean grass pollen count of 27.0grains/m3.
A post hoc analysis comprising the data from
2363 patients participating in six grass pollen–tablet
studies and seven grass pollen seasons across North
America and Europe looked at the association be-
tween the magnitude of efficacy measurements and
pollen exposure [16]. It appeared that the magnitude
of effect was highly dependent on pollen exposure.
The relative difference between placebo and active
treatment expressed in total combined symptom
score (TCS) could be predicted from the formula:
TCS= 12%= 0.35%×pollen count (p=0.003; R2= 0.66).
It is obvious that pollen AIT should be monitored
during the pollen season. It is less clear whether
peak exposure to house dust mites should be taken
into account when designing a trial. Although fluc-
tuation in house dust mite (HDM) exposure is less
pronounced in Dutch houses higher levels of Der p1
have been seen August–October compared to Jan-
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uary–May. These high levels were accompanied by
decrease in bronchial hyperreactivity [17]. However,
very few HDM studies measured allergen exposure
at baseline [18], whereas one study only determined
Der p1 before and during the study.
Characteristics of the patient
For inclusion in AIT trials patients need to be sensi-
tised to the allergen that will be evaluated, moreover
a history is required that matches with the sensitisa-
tion. For a successful trial it is obvious that room for
improvement is needed. Patients with mild disease
may not further improve on active treatment, more-
over long-lasting immunotherapy is also not intended
for such patients. There are several ways to insure
that moderate to severe rhinitis patients are being re-
cruited. Several investigators recruited patients with
poor symptom control in spite of the use of adequate
pharmacotherapy [19–23]. Alternatively, a retrospec-
tive symptom score can be used [14, 24]. The dis-
advantage of the latter approach is that these scores
can be hampered by recall bias. An observational pe-
riod or baseline assessment is also possible [25, 26]
which will lengthen the study. The importance of dis-
ease severity is underlined by a study from Howarth
evaluating 3 multicentre trials [27]. Based on symp-
tom severity patients were allocated to low, medium
and high tertiles. The treatment effect increased with
greater disease severity.
The choice of the primary endpoint
A RCT has a primary endpoint as a measure of suc-
cess of the trial. The study is ideally powered for the
primary endpoint. Separately, other endpoints of in-
terest are put forward as secondary endpoint. The va-
riety of possible endpoints in AIT trials with rhinocon-
junctivitis patients has led to a position paper on this
topic [28]. Although not validated, a combined symp-
tom medication score is currently proposed as the
standard endpoint for AIT studies in rhinitis patients.
The absence of clearly defined endpoints will hamper
progress in this field. A negative Cochrane meta-anal-
ysis on sublingual immunotherapy in asthma con-
cluded that lack of data for important outcomes such
as exacerbations and quality of life and use of different
unvalidated symptom and medication score have lim-
ited the ability to draw a clinically useful conclusion
[29]. Recently, a successful study with HDM tablets
in partly to uncontrolled asthmatics has been pub-
lished [30]. Active treatment reduced the time to de-
velop an asthma exacerbation, the primary outcome.
Asthma control and quality of life scores, secondary
outcomes, were not affected. These outcome mea-
sures were probably not suitable for the design of the
study as patients were tapering down their steroids
until the first asthma exacerbation. It is conceivable
that in this short period quality of life or asthma con-
trol would not have been substantially affected. If one
of these outcome measures were chosen as primary
outcome, the study would have failed.
Other examples of the importance of outcome
measures are the Preventive Allergy Treatment (PAT;
[31]) and Grass SLIT tablet Asthma Prevention (GAP;
[32]) study. The PAT study is a RCT to the effect of
subcutaneous grass pollen immunotherapy on the
development of asthma [31]. The hypothesis was
that immunotherapy may prevent asthma. And in-
deed, in this trial comprising 203 children among
those without asthma actively treated children had
significantly fewer asthma symptoms (odds ratio [OR]
2.52; p<0.05) after 3 years. The effect remained up to
10 years after starting treatment [33]. In contrast to
the open and controlled but not placebo-controlled
PAT study, the GAP trial, aiming to evaluate the pre-
ventive effect of SLIT, was placebo controlled with
3 years treatment and 2 years blinded follow-up [32].
A total of 812 children were included and again in
the actively treated group the risk of experiencing
asthma symptoms or using asthma medication (OR
0.66; p< 0.036) was lower. However, in the latter study
there was no difference in time to onset of asthma,
the primary outcome of the GAP study. For the diag-
nosis of asthma documentation of a reversible lung
function impairment was required. Children with
frequent episodes of asthma symptoms but a nor-
mal lung function at the time of the trial visits were
not recorded as having asthma. By choosing another
endpoint the GAP study was—from a regulator’s per-
spective—not successful, whereas the results were at
least promising.
Some studies that did not reach the primary end-
point are still considered successful or at least promis-
ing. In 2006 a small phase 2 trial of ragweed pollen
conjugated to a phosphorothioate oligodeoxyribonu-
cleotide immunostimulatory sequence of DNA con-
taining a CpG motif was reported [34]. Six pre-
seasonal injections only appeared to be clinically
effective during 2 ragweed seasons. The primary
endpoint—vascular leakage and inflammation during
nasal allergen challenge—however was not reached.
A recent study looking at the effect of recombi-
nant fusion proteins consisting of non-allergenic grass
pollen peptides and the hepatitis B preS protein re-
ported that active treatment failed to meet the pri-
mary endpoint (symptom-medication score). How-
ever a post hoc analysis with patients having spe-
cific IgE ≥3.5kUl/l demonstrated statistically signifi-
cant improvement in symptom-medication scores in
the 2nd year of treatment. In addition, visual analogue
scores and quality of life improved significantly [35].
A successful phase II peanut immunotherapy study
has been published by Sampson et al. [36]. Using
the technique of epicutaneous immunotherapy with
peanut, they demonstrated in a one year study that
active treatment generate a response rate to treat-
ment of 25% (95% confidence interval [CI] 7.7–42.3%,
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p= 0.01) over placebo. The difference was even higher
in children (34.2%; 95% CI 11.1–57.3%, p=0.08). Suc-
cessful treatment was achieved when an eliciting dose
was reached ≥10 times increase and/or ≥1000mg of
peanut protein. In a recent phase 3 study the differ-
ence in response rate over placebo was lower, but still
significant (21.7%, 95% CI 12.4–29.8%; [37]). However,
in the statistical analysis plan submitted to the FDA
it was agreed to the lower bound of the CI should be
15%. From that perspective, the aim of this study was
not reached.
One might say that success or failure of a trial is
also a matter of definition.
The placebo effect
AIT are characterised by a substantial placebo effect.
In a survey from 2013 it was shown that the mean
placebo effect in 5 SCIT trials amounts to 41% [38].
This was not seen with SLIT, but in this analysis only
1 SLIT study was included. Two recent unpublished
AIT trials were hampered by substantial placebo ef-
fects. In a field study with cat-peptides the active
treatment group showed a reduction of 61% in symp-
toms with a comparable reduction of 59.5% in the
placebo group [39]. The results were remarkable as
a phase II study evaluating efficacy by use of aller-
gen exposure chambers was successful [40]. Also
a field study with HDM peptides was hampered by
a placebo effect of around 40%, comparable with
the active treatment effects of three different doses
[41].
Large placebo effects are more rule than exception
also in successful AIT studies; thus it is difficult to
state that only the placebo effect is responsible for
the negative outcome of a study.
The difference between a phase II and III study
The abovementioned studies demonstrate that the re-
sults of phase II and III studies can differ. The phase II
and III studies may differ in design and are therefore
not fully comparable. In the cat studies not only cat
exposure differed (allergen exposure chamber versus
natural exposure), but also the study population dif-
fered with patients without cats in the phase II study
and cat-owners in the phase III study. It is a matter
of debate whether the cat owners were less likely to
respond to treatment than those who were not con-
tinuously exposed to cat allergen.
The study from Creticos et al. [34] which tested
a ragweed vaccine conjugated with a toll-like recep-
tor 9 agonist resulted in a large phase III study with
30 centres and 738 subjects. Unfortunately this study
failed to demonstrate any efficacy of the ragweed
vaccine [42]. It has been stated that the 3 patients
groups (2 doses, 1 placebo) had no measurable dis-
ease during the ragweed season. This suggests that
either there was no exposure to ragweed pollen or
the patients were misclassified not having sufficient
ragweed pollen allergy to establish a therapeutic re-
sponse.
Conclusion
There are many reasons for failure of a RCT evaluat-
ing the efficacy of AIT. Of course, the main reason for
failure is that the agent to be tested does not have
the biological activity to generate a therapeutic effect.
Modifications and new ways of administration may be
the cause. An allergenic extract may contain an insuf-
ficient amount of allergen. However, other factors that
are not related to the real efficacy of the active com-
pound may determine the outcome of trials. The de-
sign of the study, insufficient allergen exposure during
monitoring, inclusion of inappropriate patients and
choosing the wrong endpoints may lead to a negative
study result that does not represent the real efficacy
of test agent. Particularly, when a successful phase II
trial is followed by failure of phase III studies, fac-
tors that may negatively influence the outcome of the
latter studies have to be analysed. An important bar-
rier for understanding the reasons for unsuccessful
phase III trials and negative trials in general is the un-
availability of published data. Investigators should be
encouraged to publish their negative trials and edi-
tors should consider the value of such reports in their
journal.
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